Goldman Sachs
ADPT icon

Goldman Sachs’s Adaptive Biotechnologies ADPT Stock Holding History

Goldman Sachs’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-107,400
Closed -$1.25M – 6301
2025
Q2 		$1.25M Buy
+107,400
New +$976K ﹤0.01% 4531

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's ADPT Position: Q1 2026 in Review

Goldman Sachs increased its Adaptive Biotechnologies (ADPT) stake by 12% in Q1 2026, buying an estimated $5.41M and bringing the position to 3,242,077 shares worth $45M. The position accounts for 0.01% of the portfolio, ranked #1666.

Goldman Sachs first reported a position in ADPT in Q2 2019 and has held it in 28 quarters since. The position peaked at $60.9M in Q3 2020. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Goldman Sachs held 3,242,077 shares of Adaptive Biotechnologies worth $45M as of Q1 2026.
  • Goldman Sachs bought 339,808 Adaptive Biotechnologies shares in Q1 2026, an estimated $5.41M.
  • Adaptive Biotechnologies made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1666 holding.
  • Goldman Sachs first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 28 quarters since.
  • Goldman Sachs's Adaptive Biotechnologies position peaked at $60.9M in Q3 2020.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.